secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2026-05-28T11:01:07+00:00
Accession:  0001193805-26-000703
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic presents additional Phase 2 CALLIPER data for vidofludimus calcium in progressive MS at CMSC 2026
--------------------------------------------------------------------------------

- Late-breaking poster introduces novel unified endpoint Confirmed Disability Change (CDC) that consistently favored vidofludimus calcium over placebo across three statistical models.
- Patient-reported outcomes (PHQ-9) showed no worsening of depressive or suicidal thoughts; treatment satisfaction numerically favored drug over placebo at weeks 48 and 120.
- Safety data from 467 patients: TEAEs comparable (69.4% vs 68.5%), discontinuation due to TEAEs identical at 2.6% in both arms; no Hy's law cases.
- Serious adverse events low and balanced (8.1% vs 6.5%); liver-related TEAEs similar (5.2% vs 5.5%).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380526000703/0001193805-26-000703-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380526000703/e665514_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-26-000703

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer